Low Dose Naltrexone and Mast Cell Activation Syndrome
Mast cells form an important part of the body’s immune system.
They release substances including histamine and other chemical mediators as part of normal immune responses.
In Mast Cell Activation Syndrome, inappropriate mast-cell activation can contribute to symptoms affecting multiple body systems.
People may experience combinations of:
What about LDN?
LDN is sometimes discussed as a potential adjunctive treatment in MCAS because of its proposed effects on inflammatory signalling and immune regulation.
However, the clinical evidence remains limited.
For example, published literature includes case-based evidence involving patients with MCAS alongside conditions such as POTS and SIBO, rather than large definitive trials of LDN alone.
We therefore don’t describe LDN as a proven treatment for MCAS.